Inhibidores de puntos de control inmunológico: eventos autoinmunes y minería de datos
DOI:
https://doi.org/10.59681/2175-4411.v17.2025.1160Palabras clave:
minería de datos, inmunoterapia, inhibidores de puntos de control inmunológico, neoplasias, efectos colaterales y reacciones adversas relacionados con medicamentos, tecnología biomédicaResumen
Objetivo: investigar qué acontecimientos autoinmunes relacionados con el uso de inhibidores de puntos de control inmunitarios se han descubierto mediante la extracción de datos (ED) de la bibliografía. Método: Se utilizó una revisión rápida. Las bases de datos consultadas fueron la Biblioteca Virtual de Salud (BVS), Embase y Pubmed. Se seleccionaron quince estudios para el análisis. Resultados: los acontecimientos autoinmunes más frecuentes encontrados en la literatura a partir de la minería de datos sobre el uso de inhibidores de puntos de control inmunitarios fueron toxicidades renales, cutáneas, musculoesqueléticas, hematológicas, pulmonares, cardiacas y gastrointestinales, algunas de ellas mortales. Conclusión: con el uso de la inmunoterapia pueden producirse diversos eventos, lo que refuerza la necesidad de un seguimiento individualizado. Se sugiere que esta terapia sea investigada de acuerdo con el tipo de tumor, correlacionando con las características demográficas, así como el uso de tecnologías de la información para apoyar a los profesionales de la salud.
Citas
Shankar A, Wallbridge IG, Yau C, Saini D, Roy S, Bharati SJ, et al. Development of management strategies for immune-related adverse effects of immunotherapies used in oncological treatment. Asia Pac J Oncol Nurs. 2022;9(1):7-11 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35528796/
Medina P, Jeffers KD, Trinh VA, Harvey RD. The Role of Pharmacists in Managing Adverse Events Related to Immune Checkpoint Inhibitor Therapy. J Pharm Pract. 2020;33(3):338-49 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31694455/
Pedro Júnior J, Gomes JP, Gama JMBM, Sales ISL, Smit SBA, Silva MF, et al. Atualização sobre o uso da imunoterapia no tratamento do Câncer. Braz. J. Hea. Rev. [Internet]. 2023;6(3):12101-14 [citado 2025 mai 27]. Disponível em: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/60488
Johnson KB, Patel NR. Biomedical Informatics and Health Information Technology: a Critical, Pragmatic Collaboration for Clinical Transformation. J Gen Intern Med. 2020;36(2):530–2 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32323136/
Hassan M, Awan FM, Naz A, Andrés-Galiana EJ, Alvarez O, Cernea A, et al. Innovations in Genomics and Big Data Analytics for Personalized Medicine and Health Care: A Review. Int J Mol Sci[Internet]. 2022;23(9):4645 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35563034/
Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group Offers Evidence-Informed Guidance to Conduct Rapid Reviews. J Clin Epidemiol [Internet]. 2021;130(130):13–22 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33068715/
Schünke LC, Mello B, Costa CA, Antunes RS, Rigo SJ, Ramos GO, et al. A rapid review of machine learning approaches for telemedicine in the scope of COVID-19. Artif Intell Med. 2022;129 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35659388/
Schiavenato M, Chu F. PICO: What it is and what it is not. Nurse Educ Pract. 2021;56:103194 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34534728/
Rayyan. Intelligent Systematic Review [Homepage]. 2022 [citado 2025 mai 27]. Disponível em: https://www.rayyan.ai/
Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health [Internet]. 1998;52(6):377-84 [citado 2025 mai 27]. Disponível em: https://europepmc.org/article/MED/9764259
Pundole X, Sarangdhar M, Suärez-Almazor ME. Rheumatic and Musculoskeletal Adverse Events with Immune Checkpoint Inhibitors: Data from the United States Food and Drug Administration Adverse Event Reporting System. J Immunother Precis Oncol. 2019;2(3):65–73 [citado 2025 mai 27]. Disponível em: https://ouci.dntb.gov.ua/en/works/98zJLA24/
Ji H, Tang X, Dong Z, Song L, Jia Y. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. Clin Drug Investig. 2019;39(3):319–30 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30674039/
Fan Q, Hu Y, Yang C, Zhao B. Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. Int Immunopharmacol. 2019;76:105866 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/31491729/
Hasegawa S, Ikesue H, Nakao S, Shimada K, Mukai R, Tanaka M, et al. Analysis of immune‐related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. Pharmacoepidemiol Drug Saf. 2020;29(10):1279–94 [citado 2025 mai 27]. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/32869941/
Chen G, Qin Y, Fan Q, Zhao B, Mercola D, Li X. Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real‐world pharmacoepidemiology study of post‐marketing surveillance data. Cancer Med. 2020;9(18):6576-85 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32720449/
Bai X, Lin X, Zheng K, Chen X, Wu X, Huang Y, et al. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase. Endocrine. 2020;69(3):670–81 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32507965/
Hu Y, Gong J, Zhang L, Li X, Li X, Zhao B, et al. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84:106601 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/32422528/
Chen C, Wu B, Zhang C, Xu T. Immune-related adverse events associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. Int Immunopharmacol. 2021;95:107498 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33725634/
Ma R, Wang Q, Meng D, Li K, Zhang Y. Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer. 2021;21(1):38 [citado 2025 mai 27]. Disponivel em: https://pubmed.ncbi.nlm.nih.gov/33413213/
Chen C, Zhang C, Jin Z, Wu B, Xu T. Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system.Int J Clin Pharm. 2022;44(3):689-697 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35449347/
Chen C, Zhang C, Wu B, Xu T. Immune-related adverse events in older adults: Data mining of the FDA Adverse Event Reporting System. J Geriatr Oncol. 2022;13(7):1017-1022 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35660091/
Zhang P, Lao D, Chen H, Zhao B, Du Q, Zhai Q, et al. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years. Front Immunol. 2022;13:778635 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36081514/
Liu Y, Chen Y, Zeng Z, Liu A. Arrhythmic events associated with immune checkpoint inhibitors therapy: A real‐world study based on the Food and Drug Administration Adverse Event Reporting System database. Cancer Med. 2022;12(6):6637–48 [citado 2025 mai 27]. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36426382/
Shi, H., He, Y., Dan, S., Yang, L., Wang, J., Chen, L., & Chen, Z. (2024). Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system. Frontiers in medicine, 11, 1366691. https://doi.org/10.3389/fmed.2024.1366691
Lyu L, Bian S, Guan K, Zhao B. Eosinophil-induced adverse events induced by treatment with programmed cell death 1/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Int J Cancer. 2025; 157(2): 317-324. https://doi.org/10.1002/ijc.35398.
Jain P, Gutierrez Bugarin J, Guha A, Jain C, Patil N, Shen T, et al. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. ESMO Open. 2021 Oct;6(5):100252. https://doi.org/10.1016/j.esmoop.2021.100252. Epub 2021 Aug 27. Erratum in: ESMO Open. 2021 Dec;6(6):100286. https://doi.org/10.1016/j.esmoop.2021.100286.
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2025 Natália Marmitt, Sheron Tannara Vargas, Agnes Peruzzo Innocente, Diogo Ferreira Ducatti, Gabriel Ricardo Fernandes, Alessandra Dahmer, Mellina da Silva Terres
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial-CompartirIgual 4.0.
La sumisión de un artículo a el Journal of Health Informatics es entendida como exclusiva y que no esta siendo considerado para publicación en otro periódico. La permisión de los autores para la publicación de su artículo en lo JHI implica en la exclusiva autorización concedida a los editores para su inclusión en la revista. Al someter un artículo, a lo autor será solicitada la permisión electrónica de una Nota de Copyright. Una mensaje electrónica será enviada a lo autor correspondiente confirmando el recibo del manuscrito y lo aceite de la Nota de Copyright.
